News Cara Therapeutics, Inc.

Equities

CARA

US1407551092

Real-time Estimate Cboe BZX Other stock markets 12:29:42 2024-04-26 pm EDT			5-day change	1st Jan Change
0.717 ^USD	+2.43%		+8.23%	-3.71%

Mar. 22	Cara Therapeutics, Inc. Announces Resignation of Dr. Joana Goncalves as Chief Medical Officer, Effective April 16, 2024	CI
Mar. 06	Canaccord Genuity Adjusts Cara Therapeutics Price Target to $10 From $11, Maintains Buy Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference	Apr. 02	GL
Cara Therapeutics, Inc. Announces Resignation of Dr. Joana Goncalves as Chief Medical Officer, Effective April 16, 2024	Mar. 22	CI
Cara Therapeutics to Host Notalgia Paresthetica Virtual KOL Event on Wednesday, March 27, 2024	Mar. 08	AQ
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024	Mar. 07	GL
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024	Mar. 07	AQ
Canaccord Genuity Adjusts Cara Therapeutics Price Target to $10 From $11, Maintains Buy Rating	Mar. 06	MT
Transcript : Cara Therapeutics, Inc., Q4 2023 Earnings Call, Mar 04, 2024	Mar. 04
Cara: Q4 Earnings Snapshot	Mar. 04	AQ
Cara Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 04	CI
Earnings Flash (CARA) CARA THERAPEUTICS Reports Q4 Revenue $3M, vs. Street Est of $9.1M	Mar. 04	MT
Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results	Mar. 04	GL
North American Morning Briefing : Stock Futures -2-	Mar. 04	DJ
Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024	Feb. 12	GL
Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024	Feb. 12	AQ
Cara Therapeutics to Cut Workforce Up to 50%, Halt Work on Chronic Kidney Disease; Chief Scientific Officer to Exit	Jan. 22	MT
Transcript : Cara Therapeutics, Inc. - Special Call	Jan. 22
Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026	Jan. 22	GL
Cara Therapeutics, Inc. Prioritizes Late-Stage Notalgia Paresthetica Program	Jan. 22	CI
Cara Therapeutics, Inc. Announces Frédérique Menzaghi Departs as Chief Scientific Officer and SVP of Research & Development, Effective February 2, 2024	Jan. 22	CI
HC Wainwright Adjusts Price Target on Cara Therapeutics to $2.50 From $7, Keeps Buy Rating	Dec. 19	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Cara Therapeutics, Inc.

Equities

CARA

US1407551092

Summary

Filters